What is SNTI's current stock price?

As of now, SNTI is trading at $1.31, with a daily change of -7.42%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

SNTI Stock Analysis & IQ Rating | Senti Biosciences

SNTI

Senti Biosciences

$1.31

-$0.11 | -7.42%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$5.86

MKT CAP

$34.32M

52W Low

$1.26

VOL

$1.26M

P/E Ratio

N/A

AVG VOL

$2.86M

RSI

35.91

TREND

Sideways

SNTI Stock IQ

Login to see Senti Biosciences (SNTI) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

SNTI Target Price

Login to display

Strengths

SNTI Rewards

Upgraded on attractively valued

SNTI Price Performance

$1.45 (-9.66%)

$1.35 (-2.96%)

$1.99 (-34.17%)

$3.92 (-66.58%)

1year

6month

3month

1month

SNTI Risk Level

SNTI has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

Extreme

LOW

HIGH

SNTI Analysts Opinion

SNTI overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

SNTI Analysts Opinion

SNTI Analysts opinion is negative but has improved from the past 3 months

SNTI Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

90%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NA

SNTI Street Sentiment

SNTI Street Sentiment is extremely bullish and have negative views on the near-term outlook

SNTI Performance Sentiment

Sentiments overview associated with SNTI events and the stock performance.

90%

0%

Positive

Negative

9 out of 10
events present

0 out of 10
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$1.31

Resistance
Price

N/A

Current Price Range

$1.90

Show methods +

Linked to SNTI

IQ

Close Price

Change

MOLN

3.50

4.33

-3.46%

SNTI Latest Analysis +

Chardan Capital Maintains Senti Biosciences (SNTI) Buy Recommendation. Fintel reports that on December 9 2025 Chardan Capital maintained coverage of Senti Biosciences (NasdaqCM:SNTI) with a Buy recommendation. Analyst Price Forecast Suggests 380.13% Upside

Wed Dec 10, 2025

$1.49 | -3.25%

Rating

Why Is Gene Therapy Focused Senti Bio Stock Falling Today?. On Tuesday SNTI) shared new data from its ongoing trial of SENTI-202 a first-in-class CD33/FLT3 targeting Logic Gated CAR NK cell therapy in patients with relapsed .Senti Biosciences shares are retreating from recent levels. Data from 20 patients (18 with evaluable responses) were presented at the American Society of Hematology (ASH) Annual Meeting.On Tuesday the United States Food and Drug Administration (FDA) granted Regenerative Medi

Tue Dec 9, 2025

$1.54 | -35.56%

Activity

Senti Biosciences Secures FDA RMAT Designation For SENTI-202 . (RTTNews) - Senti Biosciences Inc. (SNTI) on Tuesday announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to SENTI-202 its off-the-shelf CAR-NK therapy being developed for relapsed or refractory AML and other hematologic cancers.

Tue Dec 9, 2025

$1.54 | -35.56%

Activity

Senti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial Stock Up . (RTTNews) - Senti Biosciences Inc. (SNTI) Tuesday announced new data from its ongoing trial of SENTI-202 evaluating the safety efficacy and pharmacodynamics of the treatment when administered after Fludarabine/lymphodepletion in patients with relapsed or refractory Acute My

Tue Dec 9, 2025

$1.54 | -35.56%

Activity

Momentum

Senti Announced Positive Phase 1 Data For SENTI-202 In Relapsed/ Refractory AML . (RTTNews) - Senti Biosciences Inc. (SNTI) Tuesday presented new data from its ongoing multinational Phase 1 trial evaluating SENTI-202 for treating patients with relapsed or refractory Acute Myeloid Leukemia or AML at ASH 2025.

Tue Dec 9, 2025

$1.54 | -35.56%

Activity

Senti Bio stock soars after positive cancer therapy trial results.

Tue Dec 9, 2025

$1.54 | -35.56%

Activity

Momentum

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100 Key Pharma Companies Actively Working in the Domain | DelveInsight. Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100 Key Pharma Companies Actively Working in the Domain |. DelveInsightAcute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults the global rise in aging populations i

Thu Dec 4, 2025

$2.22 | +0.91%

Activity

FAQ About SNTI Stock Insights

What is SNTI current stock price?

What are SNTI stock strengths?

What is SNTI Risk Level?

What is SNTI market cap and volume?

What is SNTI current Stock IQ?

Should I buy SNTI stock right now?

Is SNTI a Strong Buy right now?

What does a 'Strong Buy' rating mean for SNTI?

What does a 'Strong Sell' rating mean for SNTI?

What factors influence SNTI's Stock IQ?

Explore our SNTI Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored SNTI Stock Strategies
Effective Risk Management

FIND US ON

Receive our SNTI Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

SNTI

Senti Biosciences

Current Price

$1.31

-$0.11 | -7.42%

52W High

$5.86

MKT CAP

$34.32M

52W Low

$1.26

VOL

$1.26M

P/E Ratio

N/A

AVG VOL

$2.86M

RSI

35.91

TREND

Sideways

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

SNTI Rewards

Upgraded on attractively valued

Linked to SNTI

Symbol

IQ

Close

Change

MOLN

3.50

4.33

-3.46%

SNTI Price Performance

$1.45 (-9.66%)

$1.35 (-2.96%)

$1.99 (-34.17%)

$3.92 (-66.58%)

1year

6month

3month

1month

SNTI Analysts Opinion

SNTI Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

SNTI Analysts Opinion

SNTI Analysts opinion is negative but has improved from the past 3 months

SNTI Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

90%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NA

SNTI Street Sentiment

SNTI Street Sentiment is extremely bullish and have negative views on the near-term outlook

SNTI Risk Level

SNTI has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

Extreme

LOW

HIGH

SNTI Performance Sentiment

Sentiments overview associated with SNTI events and the stock performance.

90%

0%

Positive

Negative

9 out of 10
events present

0 out of 10
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$1.31

Resistance
Price

N/A

Current Price Range

$1.90

Show methods +

SNTI Stock IQ

Login to unlock Senti Biosciences (SNTI) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

SNTI Latest Analysis

Chardan Capital Maintains Senti Biosciences (SNTI) Buy Recommendation. Fintel reports that on December 9 2025 Chardan Capital maintained coverage of Senti Biosciences (NasdaqCM:SNTI) with a Buy recommendation. Analyst Price Forecast Suggests 380.13% Upside

Wed Dec 10, 2025

$1.49 | -3.25%

Rating

Why Is Gene Therapy Focused Senti Bio Stock Falling Today?. On Tuesday SNTI) shared new data from its ongoing trial of SENTI-202 a first-in-class CD33/FLT3 targeting Logic Gated CAR NK cell therapy in patients with relapsed .Senti Biosciences shares are retreating from recent levels. Data from 20 patients (18 with evaluable responses) were presented at the American Society of Hematology (ASH) Annual Meeting.On Tuesday the United States Food and Drug Administration (FDA) granted Regenerative Medi

Tue Dec 9, 2025

$1.54 | -35.56%

Activity

Senti Biosciences Secures FDA RMAT Designation For SENTI-202 . (RTTNews) - Senti Biosciences Inc. (SNTI) on Tuesday announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to SENTI-202 its off-the-shelf CAR-NK therapy being developed for relapsed or refractory AML and other hematologic cancers.

Tue Dec 9, 2025

$1.54 | -35.56%

Activity

Senti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial Stock Up . (RTTNews) - Senti Biosciences Inc. (SNTI) Tuesday announced new data from its ongoing trial of SENTI-202 evaluating the safety efficacy and pharmacodynamics of the treatment when administered after Fludarabine/lymphodepletion in patients with relapsed or refractory Acute My

Tue Dec 9, 2025

$1.54 | -35.56%

Activity

Momentum

Senti Announced Positive Phase 1 Data For SENTI-202 In Relapsed/ Refractory AML . (RTTNews) - Senti Biosciences Inc. (SNTI) Tuesday presented new data from its ongoing multinational Phase 1 trial evaluating SENTI-202 for treating patients with relapsed or refractory Acute Myeloid Leukemia or AML at ASH 2025.

Tue Dec 9, 2025

$1.54 | -35.56%

Activity

Senti Bio stock soars after positive cancer therapy trial results.

Tue Dec 9, 2025

$1.54 | -35.56%

Activity

Momentum

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100 Key Pharma Companies Actively Working in the Domain | DelveInsight. Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100 Key Pharma Companies Actively Working in the Domain |. DelveInsightAcute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults the global rise in aging populations i

Thu Dec 4, 2025

$2.22 | +0.91%

Activity

Discover SNTI Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of SNTI. We're here to help you make informed investment decisions today.

FIND US ON

Receive our SNTI Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

SNTI Stock trends

SNTI Stock performance

SNTI Stock analysis

SNTI investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNTI

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNTI

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

SNTI Stock Analysis & IQ Rating | Senti Biosciences

SNTI Stock IQ

SNTI Target Price

SNTI Risk Level

SNTI Analysts Opinion

SNTI Street Sentiment

SNTI Performance Sentiment

Technical Price Levels

Explore our SNTI Stock insights

Receive our SNTI Daily Alerts

SNTI Street Sentiment

SNTI Risk Level

Technical Price Levels

Discover SNTI Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of SNTI. We're here to help you make informed investment decisions today.

Receive our SNTI Daily Alerts

SNTI Runner Alarm